Podcasts

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Christian J. Nelson, PhD, dives into the complexities of sexual health concerns with men following cancer treatment, specifically with genitourinary cancers.

Discover key takeaways on tumor markers, the BEP vs. EP debate, and the role of surgery in stage II testicular cancer.

Daniel C. McFarland, DO; and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Oncology Decoded provides the current management of metastatic bladder cancer, recent advancements in systemic therapy, patient selection, and AE mitigation.

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may affect genitourinary cancer care.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.